Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.56 |
| ▸ | DRD4 | P21917 | 2/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.56 |
| ▸ | DRD3 | P35462 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CCR3 | P51677 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.47 |
| ▸ | KCNA3 | P22001 | 5/20 | 0.46 |
| ▸ | CCR1 | P32246 | 3/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4803819 | 0.81 | DRD2 (0.50) | DRD2DRD4OPRM1DRD3CYP2D6 | |
| SCHEMBL18015780 | 0.80 | DRD2 (0.61) | DRD2DRD4OPRM1DRD3CYP2D6 | |
| SCHEMBL6258542 | 0.79 | DRD2 (0.68) | DRD2DRD4OPRM1DRD3CYP2D6 | |
| SCHEMBL18014693 | 0.79 | DRD2 (0.59) | DRD2DRD4OPRM1DRD3CYP2D6 | |
| SCHEMBL23654620 | 0.77 | DRD2 (0.56) | DRD2DRD4OPRM1DRD3CYP2D6 | |
| SCHEMBL4484524 | 0.77 | DRD2 (0.56) | DRD2DRD4OPRM1DRD3CYP2D6 | |
| SCHEMBL8046070 | 0.77 | DRD2 (0.56) | DRD2DRD4OPRM1DRD3CYP2D6 | |
| SCHEMBL9911006 | 0.77 | DRD2 (0.56) | DRD2DRD4OPRM1DRD3CYP2D6 | |
| SCHEMBL11428691 | 0.76 | DRD2 (0.81) | DRD2DRD4OPRM1DRD3CYP2D6 | |
| SCHEMBL4014770 | 0.76 | DRD2 (0.65) | DRD2DRD4OPRM1DRD3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163773-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-04-24 | — | — | US | disclosed |
| US-20090233920-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-09-17 | — | — | US | disclosed |
| EP-1907359-A2 | 3,5-SUBSTITUTED PIPERIDINE DERIVATIVES EFFECTIVE ON RENIN-RELATED DISORDERS | Novartis AG (CH) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007006534-A2 | PIPERIDINE DERIVATIVES USEFUL IN THE DIAGNOSTIC AND THERAPEUTIC TREATMENT OF DISEASES DEPENDING ON RENIN ACTIVITY | NOVARTIS AG (CH) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233920-A1 | ORGANIC COMPOUNDS | REN, ACE, AGTR1 | DRD2 208/4885DRD4 249/4885OPRM1 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.